Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference PR Newswire SEATTLE, March 1, 2013 SEATTLE, March 1, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Cowen and Company 33^rd Annual Health Care Conference next week. The presentation is scheduled for 11:20 a.m. Eastern Time on Wednesday, March 6, 2013. The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com. About Omeros Corporation Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders. SOURCE Omeros Corporation Website: http://www.omeros.com Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor and Media Relations, +1-360-668-3701, email@example.com
Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
Press spacebar to pause and continue. Press esc to stop.